1. Ebell MH, Culp MB and Radke TJ: A Systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med 50: 384‑394, 2016.
2. Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced‑stage epithelial ovarian cancer. Nat Rev Clin Oncol 10: 211‑224, 2013.
3. Chae CS, Teran‑Cabanillas E and Cubillos‑Ruiz JR: Dendritic cell rehab: New strategies to unleash therapeutic immunity in ovarian cancer. Cancer Immunol Immunother 66: 969‑977, 2017.
4. Suzuki S, Sakata J, Utsumi F, Sekiya R, Kajiyama H, Shibata K, Kikkawa F and Nakatsura T: Efficacy of glypican‑3‑derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. OncoImmunology 5: e1238542, 2016.
5. Zhu X, Cai H, Zhao L, Ning L and Lang J: CAR‑T cell therapy in ovarian cancer: From the bench to the bedside. Oncotarget 8: 64607‑64621, 2017.
6. Haraldsen G, Balogh J, Pollheimer J, Sponheim J and Küchler AM: Interleukin‑33 ‑ cytokine of dual function or novel alarmin? Trends Immunol 30: 227‑233, 2009.
7. Liew FY, Pitman NI and McInnes IB: Disease‑associated functions of IL‑33: The new kid in the IL‑1 family. Nat Rev Immunol 10: 103‑110, 2010.
8. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al: IL‑33, an interleukin‑1‑like cytokine that signals via the IL‑1 receptor‑related protein ST2 and induces T helper type 2‑asso‑ ciated cytokines. Immunity 23: 479‑490, 2005.
9. Oboki K, Ohno T, Kajiwara N, Saito H and Nakae S: IL‑33 and IL‑33 receptors in host defense and diseases. Allergol Int 59: 143‑160, 2010.
10. Sattler S, Smits HH, Xu D and Huang FP: The evolutionary role of the IL‑33/ST2 system in host immune defence. Arch Immunol Ther Exp (Warsz) 61: 107‑117, 2013.
11. Kurowska‑Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, Komai‑Koma M, Pitman N, Li Y, Niedbala W, et al: IL‑33 induces antigen‑specific IL‑5+ T cells and promotes allergic‑induced airway inflammation independent of IL‑4. J Immunol 181: 4780‑4790, 2008.
12. Kurowska‑Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, Pitman N, Mirchandani A, Rana B, van Rooijen N, et al: IL‑33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 183: 6469‑6477, 2009.
13. Pei C, Barbour M, Fairlie‑Clarke KJ, Allan D, Mu R and Jiang HR: Emerging role of interleukin‑33 in autoimmune diseases. Immunology 141: 9‑17, 2014.
14. Wang S, Ding L, Liu SS, Wang C, Leng RX, Chen GM, Fan YG, Pan HF and Ye DQ: IL‑33: A potential therapeutic target in auto‑ immune diseases. J Investig Med 60: 1151‑1156, 2012.
15. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB and Liew FY: IL‑33 reduces the devel‑ opment of atherosclerosis. J Exp Med 205: 339‑346, 2008.
16. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN and Lee RT: IL‑33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117: 1538‑1549, 2007.
17. Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ and Hu WH: IL‑33 promotes gastric cancer cell invasion and migration via ST2‑ERK1/2 pathway. Dig Dis Sci 60: 1265‑1272, 2015.
18. Zhang P, Liu XK, Chu Z, Ye JC, Li KL, Zhuang WL, Yang DJ and Jiang YF: Detection of interleukin‑33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res 40: 1654‑1661, 2012.
19. Kim JY, Lim SC, Kim G, Yun HJ, Ahn SG and Choi HS: Interleukin‑33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene 34: 4928‑4938, 2015.
20. Liu J, Shen JX, Hu JL, Huang WH and Zhang GJ: Significance of interleukin‑33 and its related cytokines in patients with breast cancers. Front Immunol 5: 141, 2014.
21. O'Donnell C, Mahmoud A, Keane J, Murphy C, White D, Carey S, O'Riordain M, Bennett MW, Brint E and Houston A: An antitumorigenic role for the IL‑33 receptor, ST2L, in colon cancer. Br J Cancer 114: 37‑43, 2016.
22. Akimoto M, Hayashi JI, Nakae S, Saito H and Takenaga K: Interleukin‑33 enhances programmed oncosis of ST2L‑positive low‑metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis 7: e2057, 2016.
23. Tong X, Barbour M, Hou K, Gao C, Cao S, Zheng J, Zhao Y, Mu R and Jiang HR: Interleukin‑33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol Oncol 10: 113‑125, 2016.
24. Saied EM and El‑Etreby NM: The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin‑33 (IL‑33) in serous and mucinous epithelial ovarian tumours. Ann Diagn Pathol 27: 62‑68, 2017.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real‑time quantitative PCR and the 2(‑Δ Δ C(T)) Method. Methods 25: 402‑408, 2001.
26. Suzuki S, Terauchi M, Umezu T, Kajiyama H, Shibata K, Nawa A and Kikkawa F: Identification and characterization of cancer stem cells in ovarian yolk sac tumors. Cancer Sci 101: 2179‑2185, 2010.
27. Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng‑Adjei N, Yan J, Morrow MP and Weiner DB: Alarmin IL‑33 acts as an immunoadjuvant to enhance antigen‑specific tumor immunity. Cancer Res 74: 1789‑1800, 2014.
28. Gao K, Li X, Zhang L, Bai L, Dong W, Gao K, Shi G, Xia X, Wu L and Zhang L: Transgenic expression of IL‑33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett 335: 463‑471, 2013.
29. Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, Lu J, Qin W, Qi Y, Xie F, et al: Tumoral expression of IL‑33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol 194: 438‑445, 2015.
30. Millrud CR, Bergenfelz C and Leandersson K: On the origin of myeloid‑derived suppressor cells. Oncotarget 8: 3649‑3665, 2017.
31. Kolomeyevskaya N, Eng KH, Khan AN, Grzankowski KS, Singel KL, Moysich K and Segal BH: Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor‑α and interleukin‑6 in predicting reduced progression‑free survival in epithelial ovarian cancer. Gynecol Oncol 138: 352‑357, 2015.
32. Morales JK, Kmieciak M, Knutson KL, Bear HD and Manjili MH: GM‑CSF is one of the main breast tumor‑derived soluble factors involved in the differentiation of CD11b‑Gr1‑ bone marrow progenitor cells into myeloid‑derived suppressor cells. Breast Cancer Res Treat 123: 39‑49, 2010.
33. Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L, Li B, Zhao J, Jiao S and Wei H: Ascites‑derived IL‑6 and IL‑10 synergistically expand CD14+HLA‑DR‑/low myeloid‑derived suppressor cells in ovarian cancer patients. Oncotarget 8: 76843‑76856, 2017.
34. Brickshawana A, Shapiro VS, Kita H and Pease LR: Lineage(‑) Sca1+c‑Kit(‑)CD25+ cells are IL‑33‑responsive type 2 innate cells in the mouse bone marrow. J Immunol 187: 5795‑5804, 2011.
35. Mitsui H, Shibata K, Suzuki S, Umezu T, Mizuno M, Kajiyama H and Kikkawa F: Functional interaction between peritoneal meso‑ thelial cells and stem cells of ovarian yolk sac tumor (SC‑OYST) in peritoneal dissemination. Gynecol Oncol 124: 303‑310, 2012.
36. Lau TS, Chan LK, Wong EC, Hui CW, Sneddon K, Cheung TH, Yim SF, Lee JH, Yeung CS, Chung TK, et al: A loop of cancer‑stroma‑cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFα‑TGFα‑EGFR. Oncogene 36: 3576‑3587, 2017.
37. Fujikake K, Kajiyama H, Yoshihara M, Nishino K, Yoshikawa N, Utsumi F, Suzuki S, Niimi K, Sakata J, Mitsui H, et al: A novel mechanism of neovascularization in peritoneal dissemination via cancer‑associated mesothelial cells affected by TGF‑β derived from ovarian cancer. Oncol Rep 39: 193‑200, 2018.
38. Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa M, Ikeda SI, Kato T, Kiyono T, Takeshita F, Kajiyama H, Kikkawa F, et al: Malignant extracellular vesicles carrying MMP1 mRNA facilitate peri‑ toneal dissemination in ovarian cancer. Nat Commun 8: 14470, 2017.
39. Löhning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez‑Ramos JC, Levinson D, Radbruch A and Kamradt T: T1/ST2 is preferentially expressed on murine Th2 cells, inde‑ pendent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 95: 6930‑6935, 1998.
40. Xu D, Chan WL, Leung BP, Huang F, Wheeler R, Piedrafita D, Robinson JH and Liew FY: Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 187: 787‑794, 1998.
41. Baumann C, Bonilla WV, Fröhlich A, Helmstetter C, Peine M, Hegazy AN, Pinschewer DD and Löhning M: T‑bet‑ and STAT4‑dependent IL‑33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci USA 112: 4056‑4061, 2015.
42. Bonilla WV, Fröhlich A, Senn K, Kallert S, Fernandez M, Johnson S, Kreutzfeldt M, Hegazy AN, Schrick C, Fallon PG, et al: The alarmin interleukin‑33 drives protective antiviral CD8+ T cell responses. Science 335: 984‑989, 2012.
43. Gabrilovich DI and Nagaraj S: Myeloid‑derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162‑174, 2009.
44. Ribechini E, Greifenberg V, Sandwick S and Lutz MB: Subsets, expansion and activation of myeloid‑derived suppressor cells. Med Microbiol Immunol (Berl) 199: 273‑281, 2010.
45. Lim HX, Choi S, Cho D and Kim TS: IL‑33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid‑derived suppressor cells in tumor‑bearing mice. Immunol Cell Biol 95: 99‑107, 2017.
46. Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, Stempfl T, Teufel A, Schlitt HJ and Fichtner‑Feigl S: Tumor‑infiltrating, interleukin‑33‑producing effector‑memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology 61: 1957‑1967, 2015.